Equities Analysts Offer Predictions for Omnicell, Inc.’s Q3 2024 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research upped their Q3 2024 earnings per share (EPS) estimates for Omnicell in a note issued to investors on Tuesday, May 21st. Zacks Research analyst U. Biswas now anticipates that the company will earn $0.15 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for Omnicell’s current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.23 EPS, FY2024 earnings at $0.20 EPS, Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.14 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.15 EPS, FY2025 earnings at $0.51 EPS, Q1 2026 earnings at $0.22 EPS and FY2026 earnings at $0.56 EPS.

A number of other research firms have also issued reports on OMCL. Benchmark restated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company reduced their target price on Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $42.20.

Omnicell Price Performance

NASDAQ OMCL opened at $32.63 on Thursday. Omnicell has a 1 year low of $25.69 and a 1 year high of $77.14. The stock’s 50-day moving average price is $28.77 and its two-hundred day moving average price is $31.26. The company has a market cap of $1.50 billion, a PE ratio of -70.93, a PEG ratio of 116.26 and a beta of 0.77. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of OMCL. Covestor Ltd boosted its position in Omnicell by 65.6% during the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after purchasing an additional 537 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Omnicell during the 3rd quarter valued at about $62,000. Neo Ivy Capital Management bought a new stake in shares of Omnicell in the 3rd quarter valued at approximately $78,000. Fifth Third Bancorp increased its holdings in Omnicell by 143.2% in the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock worth $100,000 after buying an additional 1,313 shares during the last quarter. Finally, EntryPoint Capital LLC raised its position in Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.